| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL1443 | Name | VIM2P | Aliases | VIM2; VIMP1; lncRNA-CIR | |
| Species | Homo sapiens | Chromosome | 6 | Start site | 126602356 | |
| End site | 126603649 | Chain | minus | Exon NO. | 0 | |
| Assembly | Ensembl Release 89 | Class | N/A | NCBI accession | N/A | |
| Ensembl | ENSG00000220548 | Sequence | N/A | |||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| osteoarthritis | qPCR,microarray,Western blot, and immunofluorescence analyses | OA cartilage and normal cartilage | up-regulated | interaction | LncRNA-CIR contributes to ECM degradation and plays a key role in the pathogenesis of OA. | 24757148 | |||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| MMP13 and ADAMTS5 | RNA-Protein | regulation | Silencing of lncRNA-CIR by small interfering RNA promoted the formation of collagen and aggrecan and reduced the expression of matrix-degrading enzymes, such as MMP13 and ADAMTS5. | 24757148 | |||||